NO992260D0 - Rekombinant bicistronadenovirus for behandling av patologiske tilstander forbundet med dyslipoproteinemi - Google Patents

Rekombinant bicistronadenovirus for behandling av patologiske tilstander forbundet med dyslipoproteinemi

Info

Publication number
NO992260D0
NO992260D0 NO992260A NO992260A NO992260D0 NO 992260 D0 NO992260 D0 NO 992260D0 NO 992260 A NO992260 A NO 992260A NO 992260 A NO992260 A NO 992260A NO 992260 D0 NO992260 D0 NO 992260D0
Authority
NO
Norway
Prior art keywords
bicistronadenovirus
dyslipoproteinemia
recombinant
treatment
conditions associated
Prior art date
Application number
NO992260A
Other languages
English (en)
Other versions
NO992260L (no
Inventor
Patrick Benoit
Nicolas Duverger
Didier Rouy
Sandrine Seguret
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of NO992260D0 publication Critical patent/NO992260D0/no
Publication of NO992260L publication Critical patent/NO992260L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
NO992260A 1996-11-15 1999-05-10 Rekombinant bicistronadenovirus for behandling av patologiske tilstander forbundet med dyslipoproteinemi NO992260L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9613969A FR2755975B1 (fr) 1996-11-15 1996-11-15 Virus recombinants bicistroniques utiles pour le traitement de pathologies liees aux dyslipoproteinemies
PCT/FR1997/002043 WO1998022606A1 (fr) 1996-11-15 1997-11-13 Adenovirus recombinants bicistroniques pour le traitement de pathologies liees aux dyslipoproteinemies

Publications (2)

Publication Number Publication Date
NO992260D0 true NO992260D0 (no) 1999-05-10
NO992260L NO992260L (no) 1999-05-10

Family

ID=9497670

Family Applications (1)

Application Number Title Priority Date Filing Date
NO992260A NO992260L (no) 1996-11-15 1999-05-10 Rekombinant bicistronadenovirus for behandling av patologiske tilstander forbundet med dyslipoproteinemi

Country Status (14)

Country Link
EP (1) EP0941355A1 (no)
JP (1) JP2001506488A (no)
KR (1) KR20000053320A (no)
AU (1) AU721654B2 (no)
BR (1) BR9712957A (no)
CA (1) CA2271437A1 (no)
CZ (1) CZ170399A3 (no)
FR (1) FR2755975B1 (no)
HU (1) HUP9904500A3 (no)
IL (1) IL129823A0 (no)
NO (1) NO992260L (no)
SK (1) SK63499A3 (no)
WO (1) WO1998022606A1 (no)
ZA (1) ZA9710271B (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1064392A2 (en) * 1998-03-16 2001-01-03 Introgen Therapeutics, Inc. Multigene vectors
WO2001011063A2 (de) * 1999-08-10 2001-02-15 Develogen Ag Für Entwicklungsbiologische Forschung Kombinationsvektoren für den gentransfer, verfahren zu ihrer herstellung und ihre verwendung
FR2799472B1 (fr) * 1999-10-07 2004-07-16 Aventis Pharma Sa Preparation d'adenovirus recombinants et de banques adenovirales
JP2004511203A (ja) * 2000-03-24 2004-04-15 セル　ジェネシス　インコーポレーティッド 内部リボソーム接近部位を含む細胞特異的なアデノウイルスベクター
US6544780B1 (en) 2000-06-02 2003-04-08 Genphar, Inc. Adenovirus vector with multiple expression cassettes
US7179659B2 (en) 2001-04-02 2007-02-20 Agilent Technologies, Inc. Sensor surfaces for detecting analytes and methods of use
EP2741766B1 (en) * 2011-08-08 2015-10-07 Aptalis Pharma Limited Method for dissolution testing of solid compositions containing digestive enzymes
WO2021031551A1 (zh) * 2019-08-19 2021-02-25 南京诺惟生物科技有限公司 一种调控脂质代谢的复制型溶瘤腺病毒及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0598029B1 (en) * 1991-08-07 2002-02-27 ANDERSON, W., French Retroviral vectors containing internal ribosome entry sites
GB9125896D0 (en) * 1991-12-05 1992-02-05 Almond Jeffrey W Bicistronic viruses
FR2704556B1 (fr) * 1993-04-30 1995-07-13 Rhone Poulenc Rorer Sa Virus recombinants et leur utilisation en thérapie génique.
FR2722208B1 (fr) * 1994-07-05 1996-10-04 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
AU704391B2 (en) * 1994-10-28 1999-04-22 Trustees Of The University Of Pennsylvania, The Improved adenovirus and methods of use thereof
FR2731710B1 (fr) * 1995-03-14 1997-04-30 Rhone Poulenc Rorer Sa Virus recombinants exprimant la lecithine cholesterol acyltransferase et utilisations en therapie genique

Also Published As

Publication number Publication date
ZA9710271B (en) 1998-08-21
HUP9904500A3 (en) 2002-01-28
EP0941355A1 (fr) 1999-09-15
SK63499A3 (en) 2000-05-16
BR9712957A (pt) 2000-02-01
JP2001506488A (ja) 2001-05-22
FR2755975B1 (fr) 1999-05-07
NO992260L (no) 1999-05-10
CZ170399A3 (cs) 1999-08-11
CA2271437A1 (fr) 1998-05-28
HUP9904500A2 (hu) 2000-05-28
FR2755975A1 (fr) 1998-05-22
WO1998022606A1 (fr) 1998-05-28
AU5125298A (en) 1998-06-10
AU721654B2 (en) 2000-07-13
IL129823A0 (en) 2000-02-29
KR20000053320A (ko) 2000-08-25

Similar Documents

Publication Publication Date Title
PT936908E (pt) Derivados anticonvulsivos uteis no tratamento de esclerose lateral amiotrofica (ela)
NO20005864D0 (no) Quinasoler til behandling av hjernesvulst
FI971568A (fi) Menetelmä resistenttien kasvainten hoitamiseksi
NO20005884D0 (no) Kombinasjonsterapi for behandling av bipolare forstyrrelser
DK0752870T3 (da) Anvendelse af Mycobacterium til behandling af tumorer
NO991459L (no) Anvendelse av 1-hydroksy-2-pyridoner til behandling av hudinfeksjoner
ID27214A (id) Triazolopiridina untuk pengobatan gangguan trombosis
NO992260L (no) Rekombinant bicistronadenovirus for behandling av patologiske tilstander forbundet med dyslipoproteinemi
FI962420A0 (fi) Foerstaerkare med laogbrus
NO991734D0 (no) Pyrazolinoner for behandling av potensforstyrrelser
NO984189D0 (no) Fremgangsmåte for behandling av bipolar forstyrrelse
NO20003481D0 (no) FremgangsmÕte for behandling av COPD
NO991158L (no) FremgangsmÕte for behandling av amyotrofisk lateralsklerose
NO920983L (no) Fremgangsmaate for behandling av nevrodegenerative tilstander
DE69616508T2 (de) Kakaobohnenbehandlung
DE9414208U1 (de) Beschlagunterteil
NO20002481D0 (no) Kombinasjonsterapi for behandling av AIDS
NO952411D0 (no) Midler for behandling av metaboliske bensykdommer
IT1281294B1 (it) Gioiello e procedimento per la realizzazione dello stesso.
IT1277048B1 (it) Procedimento per la preparazione di cefalosporine attraverso ciclizzazione riduttiva dicarbonilica per trattamento con
NO962812D0 (no) Fremgangsmåte for behandling av nervebetennelse
KR960022630U (ko) 용광로의 풍구
NO996166L (no) FremgangsmÕte for behandling av avluter
KR960003453U (ko) 텔레비전의 상하각도 조절장치
UA25833C2 (uk) Засіб для лікуваhhя мелаhомобластом